medigraphic.com
ISSN 1561-3046 (Electronic)

2012, Number 4

<< Back Next >>

Rev Cub Med Mil 2012; 41 (4)

Progression of metabolic deterioration in first and second degree relatives of type-2 diabetic patients

Alonso MM, Torres PL, Fernández-Britto RJE, González SO, Arpa GÁ

Language: Spanish
References: 25
Page: 370-378
PDF size: 62.17 Kb.


ABSTRACT

Introduction: the onset of type-2 diabetes mellitus proceeds several years from the clinical diagnosis and it is associated with atherogenic risk factors and family history of this disease.
Objective: to identify the presence and evolution of such factors, and carbohydrate metabolism disorders in relatives of diabetic patients.
Methods: a cohort study in 113 subjects, first-and second-degree relatives of patients who have type-2 diabetes and who had no known disorders of glucose metabolism. Twice a year, blood pressure, body mass index, lipid profile, blood glucose (fasting and postprandial), insulin and insulin resistance were measured.
Results: high mean values were found for body mass index, blood pressure and lipids, which increased in an evolutionary form. 90 new patients were diagnosed with disorders of this metabolism and a progressive deterioration of glucose metabolism; insulin resistance and insulin secretion were showed.
Conclusions: the first-and second-degree relatives of patients with type-2 diabetes have a high prevalence of atherogenic risk factors, and they evolve into progressive deterioration of these factors and glucose homeostasis.


REFERENCES

  1. Fernández-Britto JE. La lesión aterosclerótica: estado del arte a las puertas del siglo XXI. Rev Cubana Invest Bioméd. 1998;17(2):114-21.

  2. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010;33:S62-9.

  3. Smushkin G, Vella A. Genetics of type 2 diabetes. Curr Opin Clin Nutr Metab Care. 2010;13: 471-7.

  4. Arpa GA, González SO. Diferentes formas de valorar el sobrepeso o la obesidad y su relación con el síndrome metabólico. Rev Cubana Med Milit. 2009 [citado 28 Oct 2012 ];38(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-65572009000200003&lng=es&nrm=iso&tlng=es

  5. Kela R, Sirinivasan B, Davies M. Glycaemic management of type 2 diabetes. Medicina. 2010;38(11):618-25.

  6. Mathews D, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and B cell function from fasting plasma and insulin concentration in man. Diabetología. 1985;28:412-49.

  7. Marianne AB van der Sande, Gijs EL Walraven. Antecedentes familiares: una oportunidad para intervenir precozmente y mejorar el control de la hipertensión, la obesidad y la diabetes. Bull WHO. 2001;79 (4):3218.

  8. Costa. Intolerancia a la glucosa. Ese frágil umbral hacia la diabetes mellitas. Standards of medical care in diabetes. Care. 2007;30(Suppl 1):4-41.

  9. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hyperinsulinemia in patients with high blood pressure. J Inter Med. 1992;231:235-40.

  10. Bloomgarden ZT. Second World Congress on the insulin resistance syndrome. Diabetes Care. 2005;28:2073-80.

  11. Baenz-Diez JM, Bermúdez-Chillido N, Mundet X, et al. Glucemia basal alterada y riesgo de diabetes mellitus a los 10 años. Estudio de cohorte. Med Clín. 2010;133:258-62.

  12. Brotons C, de la Figueroa M, Franch J, et al. Predicción de la glucemia basal alterada y resistencia a la insulina mediante el uso de medidas antropométricas de adiposidad central: estudio PRED-IR. Med Clín. 2008;131:366-70.

  13. Bays H, Dujovne CA. Adiposopathy is a more rational treatment targe for metabolic disease than obesity alone. Curr Ahteroscler Rep. 2006;8:144-56.

  14. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 2006;1:389-420.

  15. Bays H, Rodbard RW, Schorr AB, et al. Adiposopathy: treating pathogenic adipose tissue to reduce cardiovascular disease risk. Curr Treat Options Cardiovasc Med. 2007;9:259-71.

  16. Hans TS, Lean ME. Metabolic syndrome. Medicine. 2010;39:24-31.

  17. Lemieux I, Poirier P, Bergeron J, et al. Hypertriglyceridemic waist: A preventive screening phenotype. Can J Cardiol. 2007;23:23B-31B.

  18. Arsenault BJ, Lemieux I, Després JP, et al. The hypertriglyceridemic waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study. CMAJ. 2010;182(13):1427-32.

  19. Kwiterovich PO. Clinical relevance of the biochemical metabolic and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90:30-47.

  20. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241-50

  21. Bock G, Dalla Man C, Campioni M, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 2006;55:3536-49.

  22. Smushkin G, Velia A. What is type 2 diabetes? Medicine. 2010;38(11):597-601.

  23. Ioannov GN, Bryson CL, Boyko EJ. Prevalence and trends of insulin resistance impaired fasting glucose and diabetes. J Diabetes Complications. 2007;21(6):363-70.

  24. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes. Diabetes Care. 2008;31:1898-1904.

  25. González Suárez RM, Arranz Calzado MC, Perich Amador P. Trastorno de la sensibilidad a la insulina y de la tolerancia a la glucosa en la diabetes inicial. Rev Cubana Endocrinol. 2000;11(2):69-77.




2020     |     www.medigraphic.com